IP Library › Granted Patent US 8,143,211
Granted Patent B2
US 8,143,211 · App. 12/217,160 · Granted Mar 27, 2012

Bioactive peptides

Assignee: Lytix Biopharma AS
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,143,211
App. No.
12/217,160
Granted
Mar 27, 2012
Kind
B2
Abstract

The present invention provides a cytotoxic 7 to 25-mer peptide with three or more cationic residues which has one or more non-generic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing the peptides, pharmaceutical compositions containing them, and their use as medicaments, particularly as antibacterial or antitumor agents.

Claims (14)

1. A method of treating tumours in a patient in need of such treatment comprising the administration to said patient of a peptide selected from the group consisting of a cytotoxic 7-25 mer peptide with three or more cationic residues, modified at its N-terminal amino acid by a lipophilic cyclic group comprising 5 non-hydrogen atoms; a cytotoxic 7-25 mer peptide with three or more cationic residues, modified at its C-terminal amino acid by a lipophilic group comprising at least 6 non-hydrogen; and esters, amides, salts and cyclic derivatives of said peptides.

2. The method of claim 1 wherein said peptide has 7-15 amino acids.

3. The method of claim 1 wherein said lipophilic cyclic group comprises 6 non-hydrogen atoms.

4. The method of claim 1 wherein said lipophilic cyclic group is a polycyclic group wherein the cyclic groups are fused or bridged.

5. The method of claim 1 wherein said peptide has a di- or tri-alkylated N-terminal amine.

6. The method of claim 1 wherein said lipophilic cyclic group is an alkyl group having the formula CH 3 (CH 2 ) n , wherein n is between 5 and 20.

7. The method of claim 1 wherein said lipophilic cyclic group is an alkyl group having the formula CH 3 (CH 2 ) n , wherein n is between 10 and 12.

8. The method of claim 1 wherein said lipophilic cyclic group is an acyl group having between 6 and 21 carbon atoms.

9. The method of claim 1 wherein said lipophilic cyclic group is an acyl group having between 11 and 13 carbon atoms.

10. The method of claim 1 wherein said lipophilic cyclic group (R) is attached to the N-terminal amine via a linking moiety selected from a carbonyl group (RCO), carbamate (ROCO), a linker which forms urea (RNHCO or R 2 NCO) or by a linker which forms a sulfonamide, boronamide or phosphoramide.

11. The method of claim 1 wherein said peptide has a lipophilic group comprising at least 4 non-hydrogen atoms attached to its C-terminal carboxy group.

12. The method of claim 1 wherein said lipophilic group has 10 or more non hydrogen atoms.

13. The method of claim 1 wherein said lipophilic group incorporates a cyclic group.

14. The method of claim 1 wherein said lipophilic group (R) is attached to the C-terminal carboxy group via a linking moiety selected from OR, NH—R, NR 2 and B—(OR) 2 .

Priority Claims (1)
GB 9818938.4 · Aug 28, 1998 · national
Continuity (3)
Continuation 09798026 · Feb 27, 2001
Continuation PCTGB9902850 · Aug 31, 1999
Related Publication 20080287346A1 · Nov 20, 2008